Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin B Kim

Showing results (121-130 of 134) with videos related to

Pageof 14
Sort By:
Elife|February 19, 2026
Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signalingHarina Vin, Sandra S Ojeda, Grace Ching, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Pageof 14

Showing results (121-130 of 134) with videos related to

Sort By:
Pageof 14
Elife|February 19, 2026
Correction: BRAF inhibitors suppress apoptosis through off-target inhibition of JNK signalingHarina Vin, Sandra S Ojeda, Grace Ching, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2016
Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With TrametinibGeorgina V Long, Jeffrey S Weber, Jeffrey R Infante, et al.
The New England Journal of Medicine|February 24, 2012
Survival in BRAF V600-mutant advanced melanoma treated with vemurafenibJeffrey A Sosman, Kevin B Kim, Lynn Schuchter, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 19, 2013
Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skinF Stephen Hodi, Christopher L Corless, Anita Giobbie-Hurder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 8, 2014
Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600-mutant melanoma experiencing progression with single-agent BRAF inhibitorDouglas B Johnson, Keith T Flaherty, Jeffrey S Weber, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 10, 2013
Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanomaKerstin Trunzer, Anna C Pavlick, Lynn Schuchter, et al.
The New England Journal of Medicine|October 23, 2023
Three-Year Overall Survival with Tebentafusp in Metastatic Uveal MelanomaJessica C Hassel, Sophie Piperno-Neumann, Piotr Rutkowski, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2024
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced MelanomaOmid Hamid, Karl D Lewis, Amy Weise, et al.
Lancet (London, England)|January 21, 2024
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S Weber, Matteo S Carlino, Adnan Khattak, et al.
JAMA Oncology|April 29, 2016
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical TrialGuo Chen, Jennifer L McQuade, David J Panka, et al.
Pageof 14